IL-17
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 4 months ago
2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU
Robert B Chao, MD doctorRBC
4 years 4 months ago
Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab
⭐️mean change and resolution of enthesitis similar
⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity
⭐️rate of relapse ⬇️ and similar
Abs#POS0194
#EULAR2021 @RheumNow https://t.co/uPE4kmotCY
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
1. EULAR2021 - Day2a
2. EULAR2021 - Day2b
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop recommendations, based upon the best scientific evidence, for the optimal treatment of patients with PsA” Dr.
Eric Dein ejdein1
4 years 4 months ago
#EULAR2021 POS0226 Bimekizumab (anti-IL17A and IL-17F) 160 mg Q4w for AS, 3yr phase 2b, open-label extension wk 48-156). Efficacy sustained ASAS40 63%. AEs: pharyngitis, URI, bronchitis, ⬆️ ALT, oral candida (mild/mod). @RheumNow.
Robert B Chao, MD doctorRBC
4 years 4 months ago
IL-17i expressed in overuse tendinopathy. Secukinumab for tx of rotator cuff tendinopathy?
⭐️Phase II study - no difference in rotator cuff score (WORC) vs placebo
⭐️no difference in pain score
Abs#POS0022
#EULAR2021 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD
4 years 4 months ago
➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi
➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l
#EULAR2021 @Rheumnow https://t.co/faT3M0xQiR
Robert B Chao, MD doctorRBC
4 years 4 months ago
I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus
⭐️⬇️AS activity w/ or w/o MRI sacroilitis
Abs#OP0142
#EULAR2021 @RheumNow
Robert B Chao, MD doctorRBC
4 years 4 months ago
⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD
⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD
⭐️No overall increase in all CA: RTX, TOCI
⭐️Abatacept 1.21HR for all cancer, mainly NMSC
⭐️needs more data on JAKs, IL-17, IL-23
Abs#6916
#EULAR2021 @RheumNow
ARD & RMD Open ARD_BMJ
4 years 4 months ago
From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021.
“SpA” talk by Prof. Désirée van der Heijde.
Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏
/TK https://t.co/JFr3VC8sXY
Dr. Rachel Tate uptoTate
4 years 4 months ago
COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements in disease activity & QoL. No new safety signals. #EULAR2021 poster #POS0912 @RheumNow https://t.co/W2YoyA4K14 https://t.co/lv0GLU2WTF
Dr. Rachel Tate uptoTate
4 years 4 months ago
COAST-V: IXE ⬇️SP-N & spinal pain in r-axSpA pts w/ or w/o ⬆️ CRP or morning stiffness. Pts treated w/ ADA re-randomized to IXE showed further⬇️in SP-N & spinal pain. Poster #POS0901 #EULAR2021 @RheumNow https://t.co/46qiqrohbX https://t.co/uB15oTwztV
Dr. Rachel Tate uptoTate
4 years 4 months ago
ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm
Poster Hall